---
title: "Earnings Scheduled For September 25, 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300125437.md"
description: "Companies Reporting Before The Bell• Tamboran Resources (NYSE:TBN) is estimated to report quarterly loss at $0.30 per share on revenue of $3.82 million. Companies Reporting After The Bell• Inventiva (NASDAQ:IVA) is expected to report quarterly loss at $0.20 per share on revenue of $10.00 million. This article was generated by Benzinga's automated content engine and reviewed by an editor."
datetime: "2026-09-25T11:11:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300125437.md)
  - [en](https://longbridge.com/en/news/300125437.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300125437.md)
generator: "portal-rs"
---

# Earnings Scheduled For September 25, 2026

### Companies Reporting Before The Bell

• Tamboran Resources (NYSE:TBN) is estimated to report quarterly loss at $0.30 per share on revenue of $3.82 million.

### Companies Reporting After The Bell

• Inventiva (NASDAQ:IVA) is expected to report quarterly loss at $0.20 per share on revenue of $10.00 million. 

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [TBN.US](https://longbridge.com/en/quote/TBN.US.md)
- [IVA.US](https://longbridge.com/en/quote/IVA.US.md)

## Related News & Research

- [J.P. Morgan Raises Inventiva Voting Rights to 5.21%](https://longbridge.com/en/news/305310429.md)
- [IVA: NATiV3 readout could shape lanifibranor’s MASH opportunity and path to a 2028 launch](https://longbridge.com/en/news/304901164.md)
- [Inventiva Publishes Presentation on Lanifibranor's Antifibrotic Effects in Preclinical Models](https://longbridge.com/en/news/305136113.md)
- [Sofinnova Crossover I’s Voting Rights in Inventiva Rise to 5.55%](https://longbridge.com/en/news/304510993.md)
- [Inventiva shareholders reject employee share plan capital increase proposal at June 30 AGM](https://longbridge.com/en/news/291583680.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**